Now Playing
Opinion|Videos|October 25, 2023
Management Insights for Patients With Hemophilia
Russell P. Gollard, MD, FACP, discusses hemophilia patients in their plan, identifying these patients, and treatment with newer monoclonal factor products.
Episodes in this series
Russell P. Gollard, MD, FACP: We have approximately 3 dozen patients in our plan with hemophilia A. Many of those patients present with either a family history or with a proclivity toward bleeding. In young people with severe disease, OOftentimes, this will be something that’s identified at birth when the umbilicus is cut. Other than that, we see playground injuries. We see epistaxis quite often. In young ladies, we will oftentimes see some excessive menstruation. Now, I should say that as this is a sex-linked disease, it’s much more common in males than in females, but there are women with the disease.
In our plan, we manage treatments for rare diseases. These patients are not referred out of state. We are in Las Vegas, Nevada. There is a hemophilia treatment center here that we work with, but we also manage those patients through our own clinics. These patients need to be identified and followed. They are seen in the clinic with some frequency. In some cases, they’re seen at a hemophilia treatment center where there is a full-time nurse practitioner practicing. Many of these patients are very, very active in the management of their own disease and know how to prophylax themselves. Usually, patients get 1 of the newer monoclonal factor 8 products, and these are then given with some frequency, sometimes 3 times a week, sometimes less, depending on the severity of the disease and its penetrance in these patients.
Transcript is AI generated and reviewed by an AJMC editor.
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5